A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...
Patients with GCA or AAV were associated with an increased risk for hospitalization due to pneumonia compared with members of the general population.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and ...
NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling ...
As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...
As of Thursday, January 08, Corvus Pharmaceuticals, Inc.’s CRVS share price has dipped by 6.45%, which has investors ...
The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...
Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system homeostasis. When the immune system malfunctions, irregularities in cytokine ...
IDOR-1117-2520 is now in a Phase 2 proof-of-concept trial in psoriasis, with the potential to expand into additional autoimmune conditions where the CCR6-CCL20 pathway plays a pathogenic role.
Response and remission rates failed to beat placebo in a new Harvard meta-analysis, throwing the inflammation hypothesis into question. But about 15 years ago, psychiatry had already begun moving to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback